Alpha-Emitters and Targeted Alpha Therapy in Oncology: from Basic Science to Clinical Investigations
- 8 February 2018
- journal article
- review article
- Published by Springer Science and Business Media LLC in Targeted Oncology
- Vol. 13 (2), 189-203
- https://doi.org/10.1007/s11523-018-0550-9
Abstract
Alpha-emitters are radionuclides that decay through the emission of high linear energy transfer α-particles and possess favorable pharmacologic profiles for cancer treatment. When coupled with monoclonal antibodies, peptides, small molecules, or nanoparticles, the excellent cytotoxic capability of α-particle emissions has generated a strong interest in exploring targeted α-therapy in the pre-clinical setting and more recently in clinical trials in oncology. Multiple obstacles have been overcome by researchers and clinicians to accelerate the development of targeted α-therapies, especially with the recent improvement in isotope production and purification, but also with the development of innovative strategies for optimized targeting. Numerous studies have demonstrated the in vitro and in vivo efficacy of the targeted α-therapy. Radium-223 (223Ra) dichloride (Xofigo®) is the first α-emitter to have received FDA approval for the treatment of prostate cancer with metastatic bone lesions. There is a significant increase in the number of clinical trials in oncology using several radionuclides such as Actinium-225 (225Ac), Bismuth-213 (213Bi), Lead-212 (212Pb), Astatine (211At) or Radium-223 (223Ra) assessing their safety and preliminary activity. This review will cover their therapeutic application as well as summarize the investigations that provide the foundation for further clinical development. Open image in new windowKeywords
This publication has 95 references indexed in Scilit:
- Gold Coated Lanthanide Phosphate Nanoparticles for Targeted Alpha Generator RadiotherapyPLOS ONE, 2013
- Selective Killing of Tumor Neovasculature Paradoxically Improves Chemotherapy Delivery to TumorsCancer Research, 2010
- Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid LeukemiaClinical Cancer Research, 2010
- Radioimmunotherapy of Breast Cancer Metastases with α-Particle Emitter 225Ac: Comparing Efficacy with 213Bi and 90YCancer Research, 2009
- Treatment of Peritoneal Carcinomatosis by Targeted Delivery of the Radio-Labeled Tumor Homing Peptide 213Bi-DTPA-[F3]2 into the Nucleus of Tumor CellsPLOS ONE, 2009
- Targeted α-particle radiotherapy with 211At-labeled monoclonal antibodiesNuclear Medicine and Biology, 2007
- Enhanced Retention of the α-Particle-Emitting Daughters of Actinium-225 by Liposome CarriersBioconjugate Chemistry, 2007
- Improved tumor imaging and therapy via i.v. IgG–mediated time-sequential modulation of neonatal Fc receptorJCI Insight, 2007
- A kit method for the high level synthesis of [211At]MABGBioorganic & Medicinal Chemistry, 2007
- Selective Alpha-Particle Mediated Depletion of Tumor Vasculature with Vascular NormalizationPLOS ONE, 2007